SCHEMBL13630512

SCHEMBL13630512

CCOC(=O)[C@@]1(NC(=O)[C@@H]2C[C@@H](Oc3nccc4cc(OC)ccc34)CN2)C[C@H]1I

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 3/20 0.39
CYP3A4 P08684 1/20 0.38
CTSB P07858 1/20 0.37
GRM4 Q14833 3/20 0.33
ALDH1A1 P00352 2/20 0.32
GSK3B P49841 1/20 0.32
MEN1 O00255 1/20 0.32
ALOX15 P16050 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TRPA1 O75762 1/20 0.32
TP53 P04637 2/20 0.32
MAPT P10636 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
RIOK2 Q9BVS4 3/20 0.32
GSK3A P49840 2/20 0.32
MAPK10 P53779 2/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13617057 0.90 CYP3A4 (0.47) ROCK2CYP3A4CTSBGRM4ALDH1A1
SCHEMBL3694454 0.90 CYP3A4 (0.47) ROCK2CYP3A4CTSBGRM4ALDH1A1
Hydrochloric Acid SCHEMBL3697893 0.89 CYP3A4 (0.47) ROCK2CYP3A4CTSBGRM4ALDH1A1
SCHEMBL8185379 0.84 CYP3A4 (0.53) ROCK2CYP3A4CTSBGRM4GSK3B
SCHEMBL13247284 0.84 CYP3A4 (0.53) ROCK2CYP3A4CTSBGRM4GSK3B
SCHEMBL13385189 0.82 CYP3A4 (0.49) ROCK2CYP3A4CTSBGRM4GSK3B
SCHEMBL13630811 0.80 CYP3A4 (0.40) ROCK2CYP3A4MEN1KMT2AMAPT
SCHEMBL12054494 0.80 ROCK2 (0.41) ROCK2CYP3A4CTSBGRM4GSK3B
SCHEMBL13630514 0.80 CYP3A4 (0.52) ROCK2CYP3A4CTSBKDM4ENPC1
SCHEMBL8174573 0.80 CYP3A4 (0.52) ROCK2CYP3A4CTSBGRM4GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285773-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285773-A1 Hepatitis C Virus Inhibitors HAVCR2, HCCS, PYGL ROCK2 3795/4885CYP3A4 379/4885CTSB 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.